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Paraquat is a herbicide. It is a highly toxic compound 
for humans often used for suicide, especially by farmers, 
and is associated with high mortality rates (1). In fact, if 
one consumes more than 20 millilitres of its 20 % solution, 
a rapid onset of multi-organ dysfunction will cause death 
within a few days. In contrast, consumption of smaller 
amounts of paraquat may respond to supportive care and 
the patient could survive the acute phase (2).
Unfortunately, the polyamine reuptake system, which 
is mainly expressed in the membrane of alveolar cells, is 
responsible for toxin accumulation in the lungs during the 
acute phase. Consequently, lung fibrosis may occur as a 
delayed complication, which may potentially be fatal (3, 
4). However, scientists propose to use anti-inflammatory 
drugs as the main part of treatment for preventing 
pulmonary fibrosis, progression to end-stage respiratory 
failure, and death within 2-3 weeks after paraquat 
intoxication  (2).
Fortunately, if the patient overcomes this phase, 
pulmonary fibrotic tissue remodelling can lead to functional 
regeneration within about 6 months (5).
To date, no clearly efficacious therapies have definitively 
been shown to alter fibrosis progression. Moreover, no 
treatment for respiratory failure due to paraquat-induced 
lung fibrosis till date has proven effective (6).
However, respiratory failure is the main reason for 
invasive mechanical ventilation, and there is no published 
study on the outcome of ventilator support. Nevertheless, 
according to recent studies evaluating the prognosis, 
respiratory failure and the need for respiratory support were 
the determinants of the fatal outcome (1). This finding is 
similar to those reported previously in patients with 
idiopathic pulmonary fibrosis (7). The probable mechanism 
is overdistension of relatively intact parts of pulmonary 
tissue and a consequent ventilator-induced lung injury or 
an increase in the right-to-left shunt flow in response to the 
prostanoid (8, 9).
In addition to fibrotic damage of the vasculature and 
elevation of vascular resistance, patients with lung fibrosis 
show decreased levels of nitric oxide (NO) production (NO 
being a significant pulmonary vasodilator), which 
contributes to pulmonary vasoconstriction and consequently 
impaired gas exchange (10, 11). This can explain a relatively 
swift progression of respiratory dysfunction in patients with 
moderate to severe paraquat toxicity.
It has previously been demonstrated that inhaled NO 
leads to preferential vasodilation in well-ventilated lung 
tissue, as well as bronchodilation, anti-inflammatory and 
antiproliferative properties (12).
Interestingly, reviewing the literature on the internet, 
one case report of successful treatment of massive paraquat 
ingestion by inhaled NO exists (13). Moreover, Cho and 
colleagues demonstrated that inhaled NO was associated 
with survival improvement in paraquat-injured rats (14).
Unfortunately, considering that fibrosis requires a long 
time to develop, continuous inhalation NO therapy presents 
technical difficulties. Sildenafil as a phosphodiesterase-5 
inhibitor stabilises cyclic guanosine monophosphate, helps 
increase NO levels in the lungs, and has selective pulmonary 
vasodilatation properties for well-ventilated lung areas (15).
Ghofrani et al. (15) demonstrated a significant 
improvement in gas exchange in patients with severe lung 
fibrosis treated with sildenafil; moreover, a controlled trial 
conducted by the idiopathic pulmonary fibrosis clinical 
research network showed a significant improvement of 
dyspnoea and quality of life, as well as pulmonary function 
stabilisation, improvement of arterial blood gas, and carbon 
monoxide diffusion capacity at 12 weeks. However, the 
latter study was unable to show a significant improvement 
of survival rates because it enrolled too few patients (11, 
15).
Moreover, it should be kept in mind that these two trials 
involved patients with severe idiopathic pulmonary fibrosis, 
which is a chronic and progressive lung disease, whereas, 
as mentioned earlier, the remodelling of fibrotic tissue can 
lead to functional regeneration in paraquat poisoning 
survivors.
According to the available safety and efficacy data, it 
seems that administration of sildenafil can theoretically 
improve ventilation–perfusion matching and thus gas 
exchange in paraquat poisoning patients (16). Therefore, a 
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